Clodronate decreases the frequency of skeletal metastases in women with breast cancer.

[1]  P. Filipponi,et al.  Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. , 1996, Bone.

[2]  C. Dunn,et al.  Etidronic Acid , 1994 .

[3]  J. Kanis,et al.  Consequences of neoplasia induced bone-resorption and the use of clodronate (review). , 1994, International journal of oncology.

[4]  J A Kanis,et al.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. , 1994, Bone.

[5]  A. Sasaki.  Parathyroid hormone-related protein(PTHrP) expression by breast cancer cells enhance osteolytic bone metastases in vivo. (口頭発表) , 1994 .

[6]  T. Spector,et al.  Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The chingford study , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  J. Hermans,et al.  Palliative pamidronate treatment in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Kanis,et al.  Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study. , 1993, European journal of cancer.

[10]  B. Thürlimann,et al.  Original article: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial , 1992 .

[11]  J. Warwick,et al.  Parathyroid hormone related protein and skeletal morbidity in breast cancer. , 1992, European journal of cancer.

[12]  E. Bruera,et al.  A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. , 1992, Journal of pain and symptom management.

[13]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[14]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Hayman,et al.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.

[16]  R. I. Cantor,et al.  An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. , 1991, Bone.

[17]  J. Kanis,et al.  The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1 , 1990 .

[18]  F. Muggia,et al.  Overview of cancer-related hypercalcemia: epidemiology and etiology. , 1990, Seminars in oncology.

[19]  D. Thiebaud,et al.  Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  M. Takigawa.  ヒト軟骨肉腫軟骨培養細胞株(HCS-2/8)。 , 1990 .

[21]  S. Ralston,et al.  COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA , 1989, The Lancet.

[22]  J. Orloff,et al.  Parathyroid hormone-like proteins: biochemical responses and receptor interactions. , 1989, Endocrine reviews.

[23]  G. Cs.  The role of the orthopaedic surgeon in the treatment of bone pain. , 1988 .

[24]  J. Hermans,et al.  REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT , 1987, The Lancet.

[25]  I. Fogelman,et al.  Combined oral contraception and skeletal bone mass , 1987 .

[26]  C. Blomqvist,et al.  Treatment of skeletal disease in breast cancer: a controlled clodronate trial. , 1987, Bone.

[27]  J. Kanis,et al.  Measuring serum calcium. , 1985, British medical journal.

[28]  A. Benson,et al.  Intravenous etidronate in the management of malignant hypercalcemia. , 1985, Archives of internal medicine.

[29]  C. Blomqvist,et al.  LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASES , 1983, The Lancet.

[30]  Hayward Jl,et al.  Assessment of response and recurrence in breast cancer. , 1978 .

[31]  G. Cs,et al.  Pathological fractures secondary to metastatic cancer. , 1974 .